Comparison of fluconazole and amphotericin B in prophylaxis of experimental Candida endocarditis caused by non-C. albicans strains.
Amphotericin B (1 mg/kg of body weight, intravenous) and fluconazole (100 mg/kg, intraperitoneal) were compared in the prophylaxis of experimental Candida endocarditis caused by drug-susceptible, non-C. albicans strains C. tropicalis and C. parapsilosis. Neither antifungal agent was effective at preventing endocarditis due to either Candida strain when either agent was administered in a single-dose regimen (1 h prior to fungal challenge); the prophylactic efficacy of both agents increased substantially when a second prophylactic dose was given (24 h postchallenge). The excellent prophylactic efficacy of fluconazole, a fungistatic agent, underscores the importance of microbistatic mechanisms in endocarditis prophylaxis.
Bayer
A S
AS
Division of Adult Infectious Diseases, Harbor-UCLA Medical Center, Torrance 90509, USA. BAYER@HUMC.EDU
Witt
M D
MD
Kim
E
E
Ghannoum
M A
MA
D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002177:Candidiasis / Q000517:prevention & control*; D004334:Drug Administration Schedule; D004696:Endocarditis / Q000517:prevention & control*; D015725:Fluconazole / Q000008:administration & dosage / Q000627:therapeutic use*; D008826:Microbial Sensitivity Tests; D011817:Rabbits
D000935:Antifungal Agents; D000666:Amphotericin B; D015725:Fluconazole